Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments

Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments GlobeNewswire November 07, 2025 Single ascending dose data readout for VTP-1000 expected before the end of 2025 Enrollment advancing in multiple ascending dose part of the AVALON trial; data expected in the second half of 2026 Proposed combination with Clywedog Therapeutics Inc. […]

Spectral Medical Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Spectral Medical Announces Third Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire November 07, 2025 PMA submission targeted for Q1 2026 following positive Tigris results and ongoing FDA interactions Company to host Corporate Update call on Wednesday, December 10, 2025 TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”)

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE(R) (setmelanotide) for Patients with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE(R) (setmelanotide) for Patients with Acquired Hypothalamic Obesity GlobeNewswire November 07, 2025 — FDA sets updated PDUFA goal date of March 20, 2026 – — Company to hold conference today at 8:00 a.m. — BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM),

Almadex Announces Plans to Drill New Hope Porphyry Project, Arizona and Provides Paradise Drill Program Update

Almadex Announces Plans to Drill New Hope Porphyry Project, Arizona and Provides Paradise Drill Program Update GlobeNewswire November 07, 2025 VANCOUVER, British Columbia, Nov. 07, 2025 (GLOBE NEWSWIRE) — Almadex Minerals Ltd. (“Almadex” or the “Company”) (TSX-V: “DEX”) is pleased to provide an update from its scout drilling program at the Paradise Project Nevada as

TERRA CLEAN PROVIDES CORPORATE UPDATE

TERRA CLEAN PROVIDES CORPORATE UPDATE GlobeNewswire November 07, 2025 Vancouver B.C., Nov. 07, 2025 (GLOBE NEWSWIRE) — TERRA CLEAN ENERGY CORP. (“Terra” or the “Company“) (CSE: TCEC, OTCQB: TCEFF, FSE: C9O0) is pleased to announce that it has scheduled its annual general meeting of shareholders for December 8, 2025 (the “Meeting“). At that Meeting, amongst

Abeona Therapeutics(R) Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation

Abeona Therapeutics(R) Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation GlobeNewswire November 07, 2025 CLEVELAND, Nov. 07, 2025 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Wednesday, November 12, 2025 at 8:30 a.m. ET to discuss its third quarter 2025 financial results

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting GlobeNewswire November 07, 2025 PHILADELPHIA, Nov. 07, 2025 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today shared two posters discussing the Company's CT-95 and

Tree Island Renews Normal Course Issuer Bid

Tree Island Renews Normal Course Issuer Bid GlobeNewswire November 07, 2025 VANCOUVER, British Columbia , Nov. 07, 2025 (GLOBE NEWSWIRE) — Tree Island Steel Ltd. (the “Company” or “Tree Island Steel“) (TSX:TSL) announced today that it has received approval from the Toronto Stock Exchange (the “TSX“) to renew its proposed normal course issuer bid to

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+(TM) at SITC 2025

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+(TM) at SITC 2025 GlobeNewswire November 07, 2025 Next generation Bria-OTS+ platform demonstrates rapid, potent and durable anti-cancer activity by activating both innate and adaptive immune responses Increased tumor cell cytotoxicity induced by both Bria-BRES+(TM) (breast cancer) and Bria-PROS+(TM) (prostate cancer) Preclinical data reinforces broad potential of Bria-OTS+ platform

Scroll to Top